The news: FDA Commissioner Marty Makary will soon be fired, according to media reports on Friday. Makary, a former Johns Hopkins surgeon, is still in charge at the time of writing, but President Donald Trump has signed off on a plan to oust him, reports say. 

Digging into the details: Makary has been under heat in the administration for several months, clashing with health agency officials and outside conservative figures on issues related to vapes, abortion pills, and vaccines. 

• Makary tried to block others in the Trump administration who pushed to approve flavored vapes and nicotine products, arguing they appeal to young conservative voters, per The Wall Street Journal.
• Anti-abortion groups have grown frustrated with the administration after the FDA approved a generic version of the abortion pill mifepristone while postponing a safety study—likely to sidestep political controversy ahead of the midterms. The leaders of multiple anti-abortion groups have called for Makary to be fired.
• Makary’s pick for vaccine chief, Vinay Prasad, had a tumultuous tenure at the agency, departing twice in the past year—most recently in March.

Why it matters: Trump’s health agencies have seen heavy turnover, and another vacancy appears to be imminent. There’s still no permanent CDC director or surgeon general, nor a confirmed replacement for Prasad. This kind of churn can slow decision-making and regulatory action, weaken responses to public health and industry needs, and erode trust in government institutions.

Implication for pharma companies: Makary’s appointment last year was generally welcomed by drugmakers, who viewed him as a more rational voice—especially compared with Health Secretary Robert F. Kennedy Jr. But sentiment cooled amid inconsistent drug review approaches (fast-tracking some with AI and a priority voucher program, while requiring additional studies for others), a crackdown on pharma advertising, and tougher vaccine safety scrutiny. Some of that, however, was more closely tied to Kennedy. The two reportedly had an increasingly contentious relationship, so if Kennedy influences Trump’s choice for the next FDA head—should Makary depart—it could be a net negative for the industry.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.